Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
Keros Therapeutics Inc KROS
$10.07
▼ -1.47%
($-0.15)
📅 Earnings This Week
Open
$10.21
Prev Close
$10.22
Day Range
$9.83 – $10.21
52W Range
$9.69 – $22.55
Market Cap
$199.30M
P/E (TTM)
2.29
Beta
1.01
EPS (TTM)
$-3.01
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-04-08 |
| Shares Out. | 19,790,000 |
| Website | kerostx.com/ ↗ |
| Phone | 16173146297 |
| Employees | 87 |
| Revenue | $367,000 |
| Gross Profit | $367,000 |
| Net Income | -$23.7M |
| Free Cash Flow | -$58.3M |
| Total Assets | $312.3M |
| Total Liabilities | $26.7M |
| Equity | $285.6M |
About Keros Therapeutics Inc
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Keros Therapeutics Inc is a publicly traded company under the ticker symbol KROS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)